|Budget Amount *help
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2013: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2011: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
1. [Utilization of the mutant-type RNAP gene (rpoB)] A variety of rifampicin-resistant mutants with mutated rpoB gene were obtained from eight actinomycete strains. These rpoB mutants displayed an enhanced activity to produce antibiotics and were found to be activated even in the silent genes, which encodes enzymes involved in secondary metabolite production. 2. [Utilization of natural mutant-type RNAP gene] By selecting for rifampicin resistance, many strains (more than 1000) with natural mutant-type rpoB were successfully isolated and characterized on antibiotic productivity. 3. [Utilization of rare earth elements] Rare earth elements such as scandium and lanthanum were found not only to enhance the productivity of antibiotics but to activate silent genes. Scandium-resistance mutation in Bacillus subtilis was found to occur in the uppS gene.